Jiafang He
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Peptidase Inhibition and Analysis, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes(2014)167 cited
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors(2003)45 cited
- → 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists(2011)25 cited
- → Isolation, Characterization, and Biological Evaluation ofSynandAntiDiastereomers of [99mTc]Technetium Depreotide: a Somatostatin Receptor Binding Tumor Imaging Agent(2007)24 cited
- → Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition(2018)18 cited
- → Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human β3 adrenergic receptor agonists(2000)17 cited
- → Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists(2010)11 cited
- → Heterocyclic acetamide and benzamide derivatives as potent and selective β3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles(2010)9 cited
- → Copper and rhenium complexes of abis(aminoethanethiol) ligand(1998)3 cited